MRNA Jun 2025 185.000 call
- Associated Press Finance
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. Moderna said it planned an approximately 20% reduction in expected research and development expenses for 2025 to 2028 from $20 billion to $16 billion. Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus.
- Barrons.com
Moderna Pulls Back on R&D and Delays Timeline for Profitability. The Stock Tumbles.
Moderna stock was slumping Thursday after it announced a major pullback in its research and development efforts, as the drugmaker seeks to stretch its cash to cover an extended period of losses. The company said it plans to cut research and development spending by 20% beginning in 2025, pausing a number of drug programs and discontinuing others. The company says those cuts will bring it to break even on an operating cash cost basis in 2028.
- Bloomberg
Moderna slashes research budget as vaccine sales disappoint
(Bloomberg) -- Moderna Inc. aims to reduce its research and development budget by about 20% over the next three years as the biotech tries to find a path to profitability following disappointing vaccine sales. Most Read from BloombergHow Americans Voted Their Way Into a Housing CrisisFor Tenants, AI-Powered Screening Can Be a New Barrier to HousingAfter a Record Hot Summer, Pressure Grows for A/C MandatesChicago Halts Hiring as Deficit Tops $1 Billion Through 2025UC Berkeley Gives Transfer Stude
